Manage episode 233865093 series 2394758
It's a battle of the big bio's on this episode of Industry Focus Healthcare. Is Gilead Sciences finally overcoming its hep C headwind? Is Amgen beating back biosimilars? We dig into the details as we discuss which of these biopharma behemoths delivered better first quarter results. Stocks: GILD, AMGN
Check out more of our content here:
1408 episodes available. A new episode about every day averaging 27 mins duration .